Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers

Inclusion Criteria: * No previous exposure to recombinant human GH (growth hormone)or IGF-I (insulin-like growth factor-I) * Body mass index (BMI) 18.0-27.0 kg/m\^2 (both inclusive) * Considered generally healthy upon completion of medical history, physical examination, vital signs, screening laboratory results, and electrocardiogram (ECG), as judged by the Investigator Exclusion Criteria: * The receipt of any investigational medicinal product within 1 month prior to this trial * Current or previous treatment with recombinant human growth hormone or IGF-I * Female of childbearing potential who is pregnant, breast-feeding or intends to become pregnant or is not using adequate contraceptive methods (adequate contraceptive measures as required by local law) for the duration of the trial * Known presence or history of malignancy * Diabetes mellitus * Use of pharmacologic doses of glucocorticoids * Use of anabolic steroids * History of drug or alcohol abuse